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Abstract
Clear cell papillary renal cell carcinoma (ccpRCC) and renal angiomyoadenomatous tumor (RAT) 
share morphologic similarities with clear cell (ccRCC) and papillary renal cell carcinoma (pRCC). 
It is a matter of controversy whether their morphologic, immunophenotypic and molecular 
features allow the definition of a separate renal carcinoma entity. The aim of our project was to 
investigate specific renal immunohistochemical biomarkers involved in the hypoxia-inducible 
factor pathway and mutations in the VHL gene to clarify the relationship between ccpRCC and 
RAT. We investigated 28 ccpRCC and 9 RAT samples by immunohistochemistry using 25 
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markers. VHL gene mutations and allele losses were investigated by Sanger sequencing and 
fluorescence in situ hybridization (FISH). Clinical follow-up data were obtained for a subset of the 
patients. No tumor recurrence or tumor-related death was observed in any of the patients. 
Immunohistochemistry and molecular analyses led to the reclassification of three tumors as 
ccRCC and TFE3 translocation carcinomas. The immunohistochemical profile of ccpRCC and 
RAT samples was very similar but not identical, differing from both ccRCC and pRCC. 
Especially, the parafibromin and hKIM-1 expression exhibited differences in ccpRCC/RAT 
compared with ccRCC and pRCC. Genetic analysis revealed VHL mutations in 2/27 (7%) and 1/7 
(14%) ccpRCC and RAT samples, respectively. FISH analysis disclosed a 3p loss in 2/20 (10 %) 
ccpRCC samples. ccpRCC and RAT have a specific morphologic and immunohistochemical 
profile but they share similarities with the more aggressive renal tumors. Based on our results, we 
regard ccpRCC/RAT as a distinct entity of renal cell carcinomas.
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Introduction
Clear cell papillary renal cell carcinoma (ccpRCC) has been proposed as a new entity of 
renal cell cancer by the International Society of Urological Pathology (ISUP) to be included 
in the next World Health Organization Classification of Renal Tumors (1). It was initially 
discovered in kidneys with end-stage renal disease in 2006 (2). Since then more than 100 
ccpRCC cases have been described and the majority were found in normal functioning 
kidneys (3–8). They are characterized by tumor cells with clear cytoplasm, linear 
arrangement of low-grade nuclei located apically distant from the basal membrane and 
containing varying amounts of tubular, papillary and cystic architecture. Strikingly, the 
ccpRCC lack mitoses, atypia, pleomorphism, necrosis, hyaline globules, foamy 
macrophages and vascular invasion. Despite significant morphologic, immunohistochemical 
and genetic similarities to clear cell renal cell carcinoma (ccRCC) and papillary renal cell 
carcinoma (pRCC), characteristic genetic differences include VHL gene mutations and 3p 
losses, found in ccRCC. Gain of the chromosomes 7 and 17 or loss of chromosome Y, are 
absent or extremely rare in ccpRCC cases (4, 9, 10). No disease defining mutation has been 
identified to date.
The renal angiomyoadenomatous tumor (RAT) was first reported in the kidney of a 93-year-
old male by Michal et al. (11). Nine years later, the same group characterized 5 additional 
tumors (12). Verine pointed out that ccpRCCs are a major differential diagnosis of RAT and 
emphasized their morphologic, immunohistochemical, molecular and clinical similarities 
(13). In the literature many terms have been used to probably describe the same entity, 
including ccRCC with prominent leiomyomatous proliferation and renal cell carcinoma with 
smooth muscle stroma (12, 14–17).
The epithelial component of ccpRCC and RAT is composed of cells with abundant clear 
cytoplasm, strong diffuse CK7 activity and low grade nuclei (Fuhrman grade 1 and 2). Due 
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to their many similarities, several authors regard ccpRCC and RAT to be a variant of the 
same entity (6, 9, 13, 17, 18).
The aims of our study were to clarify the relationship between ccpRCC and RAT and to 
identify markers to reliably distinguish ccpRCC and RAT from the biologically more 
aggressive renal neoplasms.
Materials and Methods
Case Cohort
All tumors were consultation cases from HM and EC and were received from Austria, 
France, Germany, Italy and Switzerland. Hematoxylin and eosin-stained slides were 
reviewed for morphologic features of clear cell papillary renal cell carcinoma (ccpRCC) and 
renal angiomyoadenomatous tumor (RAT) as previously described (3, 5–7, 11, 12, 19). 
Diagnostic features of ccpRCC include tumor cells with abundant clear cytoplasm, varying 
papillary, cystic and tubular architecture, low grade nuclei (Fuhrman grade 1 and 2) located 
apically distant from the basal membrane, and strong diffuse CK7 and CA-IX expression. 
For diagnosis of RAT, the following criteria were required: cells with clear cytoplasm, low 
grade nuclei (Fuhrman grade 1 and 2) embedded in a smooth muscle stroma and strong 
diffuse CK7 staining of the epithelial component. Tumors were staged according to the 
TNM system (20) and graded according to Fuhrman et al. (21). The morphologic 
characteristics were scored as previously described (7).
Immunohistochemistry
A total of 25 antibodies were selected as (i) they are involved in the VHL signaling pathway, 
(ii) they are known to be prognostic biomarkers of ccRCC and (iii) they have been reported 
as markers of ccpRCCs and RATs in a small group of ccpRCCs described in recent USCAP 
meetings (2011–2014). TMA sections (2.5 μm) were transferred to glass slides and treated 
using Ventana Benchmark XT, Bond-max (Leica Microsystems) automated systems, as well 
as manual protocols. TMA construction was not possible in five of the ccpRCC cases due to 
absence of tissue. The immunohistochemical staining product was described as nuclear, 
membranous or cytoplasmic (Table 2). The immunohistochemistry results were interpreted 
as 0 (negative), 1+ (weak staining), 2+ (moderate staining) and 3+ (strong staining). For 
statistical analysis all 2+ and 3+ stainings were defined as positive, 0 and 1+ as negative. 
Antibodies and protocols are listed in Table 2.
Fluorescence In Situ Hybridization
FISH, performed to detect VHL allele losses, was carried out using the ZytoLight ® SPEC 
VHL/CEN 3 Dual Color Probe (ZytoVision, Bremerhaven, Germany). Tissue sections were 
cut from FFPE blocks, deparaffinized and hybridized as previously described (22). Sixty 
non-overlapping tumor nuclei from three different areas were analyzed and the number of 
VHL and CEN3 signals was recorded for each nucleus. The total number of VHL and CEN3 
signals as well as the VHL/CEN3 ratio and the percentage of tumor cells with less than 2 
VHL signals were calculated. Tumors were considered VHL deleted if more than 50% of the 
tumor nuclei displayed less than 2 VHL signals (23). In two cases TFE3 FISH using SPEC 
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TFE3 Dual color break apart probe from ZytoVision were done on whole sections as 
previously described by our group (24).
VHL Sequencing Analysis
Tumor areas displaying >80% tissue in the epithelial portion of the ccpRCC and RAT were 
marked on the H&E slides. DNA from FFPE tumor tissue samples was obtained by 
punching 1–2 tissue cylinders (diameter 0.6mm) from each sample. DNA was extracted 
from the tumor tissue samples according to the Maxwell 16 FFPE Plus DNA Purification 
protocol (Promega, Fitchburg, USA) for automated DNA purification. DNA concentrations 
in the samples were measured using the Nanodrop (Thermo Fisher Scientific, Waltham, 
MA, USA). PCR of the VHL gene was performed as previously described (25) using 
approximately 40 ng of DNA for each amplification. DNA sequencing was performed with 
the dideoxy chain-termination method using the BigDye® Terminator v1.1 Cycle 
Sequencing kit (Applied Biosystems, Foster City, USA). The same forward and reverse 
primers were used for the PCR and sequencing. Cycle sequencing products were analyzed 
using the AbiPrism 3100 Genetic analyzer (Applied Biosystems). The obtained sequences 
were compared with the NCBI sequence AF010238 using NCBIs Blast 2 Sequences. All 
VHL point mutations obtained were validated by a second separate PCR and sequencing 
analysis.
Results
Clinical and Pathologic Findings
The patients with ccpRCC ranged from 29 to 75 years of age (mean age 58 years) and those 
with RAT from 32 to 68 years of age (mean age 43.3 years) at the time of nephrectomy. 
Male to female ratio was 1.5:1 in the ccpRCC group (17 men and 11 women) and 3.5:1 in 
the RAT group (6 men and 1 woman).
Clinical follow-up data was available for 78% (21/27) of the ccpRCC patients and 71% (5/7) 
of the RAT patients. Mean follow-up time was 29.7 months (range 7 to 84 months) for the 
ccpRCC patients and 32.3 months (range 25 to 38 months) for the RAT patients. There was 
no evidence of recurrence or disease-related death in any of the patients. None of the RAT 
(0/5) patients and 14 % (3/22) of the ccpRCC patients had end-stage renal disease.
In the RAT group, the average diameter of the tumor was 3.1 cm (range 1.8–5.0 cm) 
compared to 2.6 cm (range 0.5–8 cm) in the ccpRCC group. 67% (4/6) of the RAT patients 
displayed pathologic stage pT1a and 33% (2/6) stage pT1b. Overall 86% of the tumors (6/7) 
were Fuhrman nuclear grade 1 and 14% (1/7) were nuclear grade 2. In the ccpRCC cases 
77% (20/26) were stage pT1a, 19% (5/26) were pT1b and 4% (1/26) were pT2a. Fuhrman 
nuclear grade 1 was found in 48% (13/27) and nuclear grade 2 in 52% (14/27) of the tumors. 
All the ccpRCCs and 6/7 RATs showed at least focal papillary architecture and branched 
ducts. In contrast to ccpRCC, secretory cells were completely absent in the RAT cases. Both 
showed variable amounts of cystic areas. All tumors were characterized by absence of 
mitotic formations, foamy macrophages, calcifications and vascular invasion.
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Table 1 summarizes the clinicopathological findings. Morphological characteristics are 
shown in Table 5.
Immunohistochemical Findings
The immunohistochemical findings are detailed in Table 3. ccpRCC and RAT were strongly 
positive for CK7, CK19, CA-IX, GLUT-1, E-cadherin, vimentin, β-catenin, parafibromin, 
PAX-2, PAX-8, p27, p53 and c-MET. Staining for GLUT-1 (p = 0.0572), CD 70 (p = 
0.1499) and p16 (p = 0.3702) differed slightly in the RAT samples compared with ccpRCCs, 
although differences did not show statistical significance. Following the recent results by 
Cui et al. (26), Aron et al. (53) and Schwartz et al. (56), we tested parafibromin, hKIM-1 
(27) and CD133 expression to distinguish ccpRCC/RAT from ccRCC/pRCC. As shown in 
Table 4, the expression difference reached statistical significance (p <0.0001). The 
biomarkers CD70 (28), MET (29) and E-cadherin (30) were able to distinguish between 
ccpRCC/RAT and ccRCC (p <0.0001). Furthermore, the hKIM-1 and parafibromin were 
able to distinguish between ccpRCC/RAT and pRCC. All ccpRCC cases exhibited a 
characteristic CA-IX “cup-like” distribution, sparing the luminal border as it has been 
described in the literature before (6, 31). In contrast, the RAT tumors and the ccpRCC-like 
tumor with the VHL mutation showed a circumferential membranous staining pattern. Two 
RAT samples stained weakly positive for TFE3 and were, therefore, further analyzed by 
HMB45 and TFEB. Both stainings revealed a negative result. Additionally, TFE3 FISH was 
performed (see below).
Fluorescence In Situ Hybridization Findings
Three deletions of the short arm of chromosome 3 were identified. All of them occurred in 
the ccpRCC cases (3/21, 14%) and no deletion was found in the RAT cases (0/7, 0%). The 
presence of the 3p deletions in the two ccRCC controls were correctly identified. In 9 of the 
cases FISH was not performed as there was not sufficient tissue after VHL mutation analysis 
and immunohistochemistry.
TFE3 FISH was performed with the two above-mentioned RAT-like cases that showed 
weak TFE3 expression. One case showed the typical break apart pattern in >85% of the 
cells, while the second case was negative. Both cases were reclassified as translocation 
carcinomas due to immunohistochemical TFE3 positivity.
VHL Gene Mutation Analysis
Three VHL mutations were detected in the ccpRCC group (3/27, 11%) in exon 2 (c.351G>C/
p.Trp117Cys, c.461C>T/p.Pro154Leu, c.388G>C/p.Val130Leu) and one in the RAT group 
(1/7, 14%) in exon 1 (c.174_177delGCCG /p.Pro59GlyfsX7). We identified two cases, 
harboring both a VHL mutation and 3p loss. One case showed a 3p loss but no VHL 
mutation and two cases with a VHL mutation showed no 3p loss.
Discussion
In the present study we have sequenced the largest number of ccpRCC (27) and RAT (7) 
cases to date. We found a VHL mutation rate of 11% in ccpRCC and 14% in RAT. 
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Furthermore, we analyzed hypoxia-inducible factor pathway-related proteins to compare 
these findings with recent findings.
ccpRCC and RAT are currently underrecognized. Recent studies have revealed that they are 
not rare (7, 32, 33) and that among all RCC the ccpRCC have a prevalence rate between 
1.2% and 4.1%, thus representing up to 4,500 new cases of renal cancer in the United States 
annually (7, 32, 34). Awareness of its morphologic and immunohistochemical features is 
imperative for a correct classification. In a recent publication Gill et al. underscored the 
necessity of reclassifying low grade and low stage ccRCC as up to 7% of the cases are in 
fact ccpRCC (33).
Morphologically, ccpRCC and RAT share many features. Their epithelial component is 
composed of cells with clear cytoplasm and low grade nuclei. Both tumors have various 
amounts of smooth muscle stroma, and their epithelial component is characterized by either 
cystic or papillary architecture. In our cohort the majority of the RAT samples had focal 
papillary features of the epithelial component, which are typically diffuse CK7 and CA-IX 
positive. The most relevant differential diagnoses include ccRCC that exhibit papillary 
features, pRCC exhibiting clear cell characteristics and Xp11 translocation carcinoma. In 
our cohort, two cases initially classified as RAT had to be re-classified as Xp11 
translocation carcinomas after immunohistochemistry and TFE3 FISH analysis. The 
translocation carcinomas were identified by nuclear TFE3 protein expression. Only one case 
showed a positive TFE3 FISH result. It is controversial whether TFE3 positivity is sufficient 
to diagnose TFE3 translocation carcinoma (24, 35), but, from these 2 cases, we concluded 
that TFE3 translocation cancer falls within the differential diagnostic spectrum of ccpRCC/
RAT. Another differential diagnosis for the case with weak TFE3 staining and negative 
FISH is TFEB-associated RCC. Those tumors can overlap tremendously with the TFE3 
rearranged RCC (36, 37). To rule out this differential diagnosis we did two additional 
immunohistochemical stainings (HMB45 and TFEB). Both stainings showed a negative 
result making that differential diagnosis unlikely.
One ccpRCC case was reclassified as ccRCC. That case exhibited typical ccpRCC 
morphology but was completely negative for CK7 and strongly positive for hKIM-1. This 
case also revealed a mutation in the VHL gene and a 3p loss in the FISH analysis. These 
findings highlight the importance of molecular testing and should raise awareness of 
ccpRCC mimicking ccRCC (38).
VHL gene mutations are the genetic hallmark of ccRCC. Initially, it was reported that VHL 
alterations are absent in ccpRCC. However, three groups have recently identified VHL 
mutations in ccpRCC at frequencies varying from 15% to 27% (39–41). In concordance 
with these studies, we also identified VHL gene alterations in ccpRCC, but the prevalence of 
VHL gene mutations is significantly lower than in ccRCC (42–44). The discrepancy between 
the number of mutations found in our ccpRCC cases and that reported may be explained by 
the different detection methods employed, including single nucleotide polymorphism 
(SNPs) genotyping array, Sanger sequencing, and by the limited number of cases in previous 
studies. Alternatively, cases with VHL mutations could represent ccRCCs with morphology 
and immunoprofile which closely mimics that of clear ccpRCC and RAT tumor. Currently, 
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ccpRCC are diagnosed on the basis of morphology and diffuse strong CK7 expression. The 
absence of VHL mutations/3p deletions is not diagnostic for ccpRCC. Therefore we suggest 
to diagnose tumors with diffuse CK7 expression combined with the typical morphology as 
ccpRCC. In previous studies CCRCC with diffuse CK7 profile have had a completely 
different prognosis than CCRCC without that CK expression pattern (45). These previous 
findings justify such an approach. VHL inactivation leads to a HIF-dependent CA-IX and 
GLUT-1 up-regulation. We only found few VHL mutations, but in combination with CA-IX 
and GLUT-1 immunoreactivity in both ccpRCC and RAT. This clearly sets the ccpRCC and 
RAT apart from ccRCC, which shows VHL mutations in up to 80% of the cases (44, 46). 
Therefore, we believe that the HIF pathway may be activated in a VHL-independent manner 
in most ccpRCCs and RATs, also hypothesized by Rohan et al. (6).
Recently, Lawrie et al. found various mutations in ccpRCC by using Next Generation 
Sequencing (NGS), including a non-synonymous T992I mutation in the MET proto-
oncogene (47). This gene was originally described as causing hereditary pRCC (48). 
Interestingly, Lawrie et al. detected no VHL mutation, but found overexpression in all five 
members of the miR-200 family. The miR-200 family plays an essential role in tumor 
suppression by inhibiting epithelial-mesenchymal transition (49). To support Lawrie’s 
results we also noted immunoreactivity for E-cadherin and β-catenin. These findings suggest 
that epithelial-to-mesenchymal transition (EMT) may be incomplete or blocked in ccpRCC 
contributing to their indolent course (47).
Other genetic alterations characteristic for pRCC include gain of the chromosome 7 and loss 
of the chromosome Y. However, in ccpRCC, gain of the chromosome 7 have very rarely 
been reported (4, 5, 9, 10) and no loss of the chromosome Y has been observed to date. 
Fisher et al. found a unique gene expression profile of ccpRCC when investigating 8 
different genes, with only some expression levels comparable with those observed in ccRCC 
and pRCC (50).
In our FISH analysis, we identified three chromosome 3p deletions in 20 ccpRCC and in 7 
RAT samples. All 3p deletions occurred in ccpRCC with a frequency of 14.3 %, but none 
was detected in RAT. To date, only 4 cases with a 3p loss have been reported in ccpRCC 
(34, 41). Interestingly, the single case described by Martignoni et al. (41) concurrently 
harbored a VHL mutation like two of our three cases with a 3p loss. Shi et al. (34) also used 
FISH and observed monosomy of chromosome 3 in three cases in a series of 11 ccpRCC all 
lacking mutations in the VHL gene. In 2009, Shannon et al. (14) published a study on 5 
ccRCC with smooth muscle stroma and found loss of the entire chromosome 3 in two cases 
and a 3p loss in one case using FISH. In contrast, Martignoni found no 3p loss in a series of 
three cases of ccRCC with smooth muscle stroma (17). Given these molecular findings, it 
has been suggested that RAT and ccRCC with smooth muscle stroma are interchangeable 
terms (51). However, some of the cases of ccRCC with smooth muscle stroma, particularly 
those that showed 3p loss, might represent ccRCCs with exuberant, infiltrative smooth 
muscle, whereas the others might in fact be RAT tumors, particularly the ones that do not 
show 3p loss (15). Additionally, recent data shows that some tumors with RAT morphology 
and immunophenotype share a common mutation in the TCEB1 gene which inactivated the 
VHL pathway and upregulated proteins along the hypoxia-inducible pathway (52). Twenty-
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five different antibodies were used to characterize ccpRCC and RAT. We were particularly 
interested in hypoxia-inducible factor pathway-related proteins as well as other antibodies, 
which were reportedly used in small series of ccpRCC cases in the 2011 and 2014 USCAP 
meetings. This gave us the opportunity to compare immunohistochemical findings in 
ccpRCC and RAT to clarify their interrelationship. Remarkably, there were no statistically 
significant differences in the staining properties in any of the antibodies in ccpRCC 
compared to RAT.
Parafibromin and hKIM-1 expression levels differed significantly between ccpRCC/RAT 
and ccRCC/pRCC. Cui et al. (26) recently demonstrated that parafibromin can be very 
helpful in differentiating ccpRCC from ccRCC and pRCC. In a study by Aron et al. (53), the 
difference in the staining positivity rate of ccpRCC and ccRCC was even more striking 
compared with our study. In addition to parafibromin and hKIM-1 expression, CD70 also 
proved to be a useful marker in differentiating ccpRCC from ccRCC, since CD70 expression 
is rare in ccpRCC and very frequent in ccRCC. CD70 was used for immunohistochemistry 
because we have previously demonstrated that CD70 is a potential biomarker for ccRCC 
(28, 54). The importance of immunohistochemical stainings in the correct identification of 
true ccpRCC was also highlighted by Williamson et al. (55). They studied 14 ccpRCC-like 
tumors, which could not be distinguished from ccpRCC morphologically, but which showed 
a high 3p deletion frequency (82%) and showed a different immunohistochemical profile, 
with negative or localized CK7 staining as the most striking feature. These characteristics 
also led to a reclassification of one of our tumors, primarily diagnosed as ccpRCC.
Recently, Schwartz et al. studied different stem cell markers in renal cancers. They reported 
a 90 % positivity rate for OCT 3/4 in a series of 10 ccpRCC samples (56). This finding is 
discrepant to our positivity rate of 8.7%, which may be due to the use of different antibodies 
or immunohistochemical protocols. However, similarly to Schwartz et al. (56), we also 
detected a high positivity rate of stem cell marker CD133 (81.8% and 100%, respectively) in 
ccpRCC. Interestingly, Schwartz et al. reported a CD133 positivity rate of only 14% in 
ccRCC. It can therefore be concluded that CD133 is an additional tool to distinguish ccRCC 
from ccpRCC/RAT.
In concordance with Munari et al. (57), we found that about one third of ccpRCC are 
positive for GATA3, a protein crucial for the regulation of Th2 development and function. 
However, given that only a moderate staining intensity was seen in no more than 10 % of 
the tumor cells, we do not consider OCT3/4 and GATA3 as diagnostic tools to differentiate 
ccpRCC from ccRCC.
No previous studies have reported cancer-related death, vascular invasion or metastasis in 
ccpRCC (4–7, 51, 58), suggesting that the disease follows an indolent course. Benign 
biologic behavior was also observed in all RAT cases (12, 14, 59). This is comparable to 
multilocular cystic RCC, which has an excellent prognosis with no disease recurrence after 
surgery (7, 12, 59). Specific molecular alterations may account for the indolent course of 
multilocular cystic RCC. Proposals have been put forward to rename multilocular cystic 
RCC as multilocular cystic renal cell neoplasm of low malignant potential to underscore this 
specific biologic behavior (1). Our group has reported that the expression of p27, CA-IX, 
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CK7 and CK19 is associated with a better prognosis in sporadic RCC (45, 60). Interestingly, 
our ccpRCC/RAT cases stained strongly positive for all of these markers. Hence, the 
indolent clinical course of ccpRCC/RAT might in part be due to this specific signaling 
pathway. However, some of our low grade ccRCC included in our previous publications 
may in fact be unrecognized ccpRCC (33, 45).
In summary, we have demonstrated that ccpRCC and RAT cannot be distinguished from one 
another by immunohistochemistry and molecular analyses and both follow a benign clinical 
course. We regard them as a spectrum of a distinct tumor entity. Precise diagnosis is crucial 
since it has an excellent prognosis. Given the reliability of TFE3 immunohistochemistry, 
TFE3 FISH should be performed in cases with equivocal TFE3 immunohistochemistry (35). 
Taking into account the controversial relevance of the VHL mutation analysis in this 
differential diagnosis, direct VHL sequencing is not helpful in separation of ccRCC with 
prominent smooth muscle stroma from RAT. Our results suggest that a panel of antibodies 
against CK7, parafibromin and MET are a helpful tool to differentiate most ccpRCC/RAT 
from other renal tumors (Table 4). In some difficult cases VHL mutation testing and TFE3 
FISH analysis are helpful tools to distinguish ccRCC and TFE3 translocation carcinoma 
from ccpRCC/RAT (Figure 5).
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Figure 1. 
Clear cell papillary renal cell carcinoma. H&E stain (A) and typical immunohistochemical 
profile with diffuse membranous CK7 positivity (B), membranous “cup-like” CA-IX 
positivity (C), nuclear parafibromin positivity (D), hKIM-1 negativity (E) and CD133 
positivity (F).
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Figure 2. 
H&E morphology of a ccpRCC-like (A-C) and a RAT-like (D-F) case. Diagnostic features 
of ccpRCC include tumor cells with abundant clear cytoplasm, varying papillary, cystic and 
tubular architecture and low grade nuclei (Fuhrman grade 1 and 2) located apically distant 
from the basal membrane. The epithelial part of RAT tumors is composed of cells with clear 
cytoplasm, low grade nuclei (Fuhrman grade 1 and 2) embedded in a smooth muscle stroma.
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Figure 3. 
Molecular features of a ccpRCC-like (A) and a RAT-like (C) case both exhibiting a 
circumferential CA-IX staining pattern, harboring a VHL mutation (D: c.174_177delGCCG/
p.Pro59GlyfsX7; E: c.351G>C/p.Trp117Cys) and a 3p deletion detected by fluorescence in 
situ hybridization (B). The mutation sites are denoted by an arrow. The boundaries between 
exon and intron are indicated. The upper base pair letter sequence shows the wild type (WT) 
sequence (D, E). Tumor cells harbor only one VHL (green) signal and two CEN3 copies 
(orange) (B).
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Figure 4. 
ccpRCC look-alike showing classic ccpRCC morphology on the HE stain (A), however with 
a typical ccRCC immunohistochemical profile showing CK7 negativity (B), CA-IX 
positivity (C), hKIM-1 positivity (D) and proof of VHL mutation (E).
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Figure 5. 
Proposed diagnostic workflow for renal cell carcinoma showing H&E features indicative for 
ccpRCC/RAT.
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Table 3
Results of Immunohistochemistry. Percentage relates to number of interpretable cases.
Antibody ccpRCC RAT
β-catenin 95.5 85.7
Carbonic anhydrase IX 95.5 85.7
CD10 31.8 66.7
CD70 22.7 0
CD133 81.8 100
c-MET 91.3 100
Cytokeratin 7 100 100
Cytokeratin 19 88.9 100
E-cadherin 100 100
Estrogen receptor 4.3 0
GATA-3 31.8 42.9
GLUT-1 95.5 85.7
hKIM-1 23.8 0
OCT3/4 8.7 0
p16 18.2 42.9
p27 100 100
p53 72.7 71.4
Parafibromin 95.5 100
PAX-2 63.6 100
PAX-8 95.5 100
Progesterone receptor 0 0
Vimentin 95.5 100
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Table 5
Morphological characteristics of RAT and ccpRCC
# Papillary Architecture Branched Ducts Secretory Cells % Cystic
RAT
1 1f yes no 15
2 0 no no 0
3 2f yes no 65
4 1f yes no 5
5 2f yes no 0
6 1f yes no 55
7 2f yes no 15
ccpRCC
1 1 yes yes 85
2 2 yes no 10
3 3 yes yes 10
4 3 yes no 10
5 2 yes no 15
6 3 yes yes 55
7 1 yes yes 0
8 3 yes no 0
9 3 yes no 0
10 2 yes no 5
11 3 yes no 0
12 3 yes yes 40
13 1 yes yes 15
14 1 yes no 5
15 2 yes no 20
16 2 yes no 10
17 1 yes yes 15
18 3 yes yes 45
19 2 yes no 30
20 2 yes yes 20
21 2 yes no 5
22 1 yes no 10
23 3 yes yes 55
24 1 yes yes 10
25 3 yes no 35
26 2 yes yes 5
27 3 yes yes 30
f = focal
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